



JUBILANT
LIFESCIENCES

Financial Results

Quarter Ended December 31, 2017

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

NOTES:

- 1. All Financial Data in this presentation is derived from the limited reviewed Financial Results of the Consolidated entity*
- 2. The numbers for the quarter have been reclassified and regrouped wherever necessary*
- 3. Closing Exchange Rate for USD 1 at Rs. 67.93 as on December 31'16 & Rs. 63.88 as on December 31'17*

Conference Call Details

Date : January, 17, 2017

Time : 05:00 pm IST

Primary Number:	+91 22 3938 1071
Local Access Number:	3940 3977 Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers.
Toll Free Number:	USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448

Replay from : January 17 to 23, 2018

Dial in No.: +91 22 3065 2322

Playback ID: 57560#

Q3'FY18 and 9M'FY18 Results Analysis

Income Statement – Q3'FY18

Particulars	Q3'FY17	Q2'FY18	Q3'FY18	YoY Growth	QoQ Growth
	(Rs Crs)			(%)	
Total Revenue from Operations (Net of Excise)	1,458	1,642	2,068	42%	26%
Pharmaceuticals	782	860	1,101	41%	28%
Life Science Ingredients	633	738	922	46%	25%
Drug Discovery Solutions	44	44	45	2%	2%
Total Expenditure	1,126	1,336	1,651	47%	24%
Other Income	5	7	3	-37%	-55%
EBITDA from Operations					
Pharmaceuticals	247	211	245	-1%	16%
Life Science Ingredients	99	131	206	109%	57%
Drug Discovery Solutions	6	5	3	-46%	-33%
Corporate (Expenses)/Income	(15)	(14)	(23)		
Total	337	332	431	28%	30%
One time expenses	0	(19)	(11)		
Reported EBITDA	337	313	420	25%	34%
Depreciation and Amortization	73	79	82	13%	4%
Finance Cost	98	66	77	-22%	17%
Profit before Tax	166	168	261	57%	55%
Tax Expenses (Net)	48	43	48	1%	13%
Minority Interest	(1)	(3)	0		
Net Profit After Tax and Minority Interest	119	128	213	78%	66%
Normalised Profit after Tax	119	142	221	85%	55%
Earnings Per Share - Face Value Re. 1 (Rs.)	7.66	8.23	13.64		
Normalised Earnings Per Share	7.66	9.15	14.20		
		(%)		(bps)	
EBITDA Margins from Operations	23.1%	20.2%	20.8%	(228)	60
Pharmaceuticals	31.6%	24.5%	22.2%	(942)	(227)
Life Science Ingredients	15.6%	17.7%	22.3%	676	459
Drug Discovery Solutions	13.3%	10.7%	7.0%	(627)	(369)
Net Margins	8.2%	7.8%	10.3%	209	246

Financial Highlights – Q3'FY18



- **Consolidated revenue at Rs. 2,068 Crore, up 42% YoY and 26% QoQ**
 - Pharmaceuticals revenue at Rs. 1,101 Crore, contributing 53% to the revenues, up 41% YoY and 28% QoQ
 - Life Science Ingredients revenue at Rs. 922 Crore, contributing 45% to the revenues, up 46% YoY and 25% QoQ
 - Drug Discovery Solutions revenue at Rs. 45 Crore, contributing 2% to the revenues, up 2% YoY and 2% QoQ
 - International revenues at Rs. 1,482 Crore, contributing 72% to the revenues; growing 40% YoY
- **EBITDA from Operations of Rs. 431 Crore, up 28% YoY and 30% QoQ with margins of 20.8%**
 - Pharmaceuticals EBITDA of Rs. 245 Crore with margins of 22.2%
 - Life Science Ingredients EBITDA at Rs. 206 Crore; growth of 109% YoY and 57% QoQ; record margins at 22.3%
 - Drug Discovery Solutions EBITDA at Rs. 3 Crore, margins at 7.0%
- **Finance costs lower 22% YoY at Rs. 77 Crore from Rs. 98 Crore in Q3'FY17 and higher 17% QoQ from Rs. 66 Crore in Q2'FY18. Finance costs include borrowing costs of Rs. 57 Crore as against Rs. 89 Crore in Q3'FY17 and Rs. 56 Crore in Q2'FY18 and charge on Stock Settlement Instrument of Rs. 20 Crore as against Rs. 10 Crore each in Q3'FY17 and Q2'FY18**
- **Highest-ever PAT at Rs. 213 Crore, up 78% YoY and 66% QoQ, with Net Margins at 10.3% and EPS of Rs. 13.64 for Re. 1 FV; Normalized PAT after adjusting for one-time expenses stood at Rs. 221 Crore with EPS of Rs. 14.20**
- **Net Debt reduction of Rs. 159 Crore after incurring capex of Rs. 70 Crore**

Income Statement – 9M'FY18


Particulars	9M'FY17	9M'FY18	YoY Growth
	(Rs Crs)		(%)
Total Revenue from Operations (Net of Excise)	4,263	5,266	24%
Pharmaceuticals	2,300	2,776	21%
Life Science Ingredients	1,832	2,361	29%
Drug Discovery Solutions	131	130	-1%
Total Expenditure	3,223	4,205	30%
Other Income	14	17	19%
EBITDA from Operations			
Pharmaceuticals	759	708	-7%
Life Science Ingredients	318	445	40%
Drug Discovery Solutions	20	8	-60%
Corporate (Expenses) /Income	(43)	(54)	
Total	1,055	1,107	5%
One time expenses	0	(30)	
Reported EBITDA	1,055	1,078	2%
Depreciation and Amortization	216	233	8%
Finance Cost	261	212	-19%
Profit before Tax	578	633	10%
Tax Expenses (Net)	152	151	-1%
Minority Interest	0	(6)	
Net Profit After Tax and Minority Interest	426	488	15%
Normalised Profit after Tax	426	510	20%
Earnings Per Share - Face Value Re. 1 (Rs.)	27.30	31.31	
Normalised Earnings Per Share	27.30	32.77	
	(%)		(bps)
EBITDA Margins from Operations	24.7%	21.0%	(371)
Pharmaceuticals	33.0%	25.5%	(751)
Life Science Ingredients	17.4%	18.9%	149
Drug Discovery Solutions	15.5%	6.3%	(914)
Net Margins	10.0%	9.3%	(72)

Financial Highlights – 9M'FY18


- **Consolidated revenue at Rs. 5,266 Crore, up 24% YoY**
 - Pharmaceuticals revenue at Rs. 2,776 Crore, up 21% YoY, contributing 53% to the revenues
 - LSI revenue at Rs. 2,361 Crore, up 29% YoY, contributing 45% to the revenues
 - Drug Discovery Solutions revenue at Rs. 130 Crore, contributing 2% to the revenues
 - International revenues at Rs. 3,794 Crore, contributing 72% to the revenues; growing 23% YoY
- **EBITDA from Operations of Rs. 1,107 Crore with margins of 21.0%**
 - Pharmaceuticals EBITDA of Rs. 708 Crore with margins of 25.5%
 - Life Science Ingredients EBITDA at Rs. 445 Crore, up 40% YoY as compared to Rs. 318 Crore in 9M'FY17; margins at 18.9%, up from 17.4% in 9M'FY17
 - Drug Discovery Solutions segment EBITDA at Rs. 8 Crore
- **Finance costs lower 19% YoY at Rs. 212 Crore from Rs. 261 Crore in 9M'FY17. Finance costs include borrowing costs of Rs. 168 Crore as against Rs. 233 Crore in 9M'FY17 and charge on Stock Settlement Instrument of Rs. 44 Crore as against Rs. 28 Crore in 9M'FY17**
- **PAT at Rs. 488 Crore, growth of 15% YoY with Net Margins at 9.3% and EPS of Rs. 31.31 for Re. 1 FV; Normalized PAT after adjusting for one-time expenses stood at Rs. 510 Crore with EPS of Rs. 32.77**
- **Net Debt reduction of Rs. 143 Crore after Capital Expenditure of Rs. 256 Crore and Triad acquisition**

Pharmaceuticals Segment Highlights

Region-wise Revenue (Rs crs)	Q3'FY17	Q2'FY18	Q3'FY18	Mix %	YoY %	QoQ %
International	745	831	1,067	97%	43%	28%
North America	529	672	915	83%	73%	36%
Europe & Japan	138	86	85	8%	-38%	-1%
ROW	79	72	66	6%	-16%	-8%
India	37	30	34	3%	-8%	14%
Income from Operations	782	860	1,101	100%	41%	28%



Geo-wise Revenue (Rs crs)	9M'FY17	9M'FY18	Mix %	YoY %
International	2,156	2,675	96%	24%
North America	1,570	2,198	79%	40%
Europe & Japan	336	273	10%	-19%
ROW	250	204	7%	-19%
India	144	101	4%	-30%
Income from Operations	2,300	2,776	100%	21%



Pharmaceuticals Segment Highlights

- Rubyfill installation completed in three sites in the USA during Q3'FY18
- Received approval for Drax Exametazime during the year; Expect to launch in FY19
- Received USFDA approval for new pulmonary indication in Draximage DTPA in Q3'FY18
- Ramp up of CMO business underway with strong order book of US\$ 693 Million and addition of three new clients during the year
- Increasing Lyophilization capacities due to increased demand in both CMO and Allergy Therapy Products businesses
- Joint inspection of the API facility was completed by USFDA and Health Canada during the quarter. Received a compliant rating from Health Canada
- Completed capacity addition in the API plant to meet higher demand going forward
- Increasing capacity in Solid Dosage Formulations to be completed in FY19 to meet increasing requirements in EU, ROW and US markets

Regulatory Status



Regulatory Agency	Cadista USA	Roorkee India	CMO / Allergy Spokane	CMO Montreal	JDI Montreal Canada	Nanjangud India
(USA)	Mar 2017	Mar 2017	Sep 2017	Dec 2016	Sep 2017	Oct 2017
(Canada)				Oct 2017	Apr 2016	Oct 2017
(Japan)		Dec 2015	Feb 2017			May 2016
(India SLA / CDSCO)		Sep 2015				Sep 2016
(Brazil)				May – June 2016		Mar 2015
(Turkey)			Mar 2015			
(Mexico)						Aug 2015

- All sites successfully inspected and fully compliant with USFDA regulations
- Use the experience from multiple Agency inspections to enhance compliance status of all sites
- World class quality control practices
- Global quality control function reporting to the Corporate Board

Portfolio of R&D products – Filings and Approvals

Product pipeline as on December 31, 2017						
Region	Dosage (Orals)			Injectables		
	Total Filings	Approval	Pending	Total Filings	Approval	Pending
US	86	56	30	12	10	2
Canada	22	22	-	13	13	0
Europe	100	95	5	10	10	0
ROW	687	490	197	44	40	4
Total	895	663	232	79	73	6

We have a total of 974 filings across geographies

- 895 filings in Dosage (Orals)
- 79 filings in injectables
- Of this, 736 filings (663 Dosage (Orals) and 73 injectables) have been approved
- 238 filings (232 Dosage (Orals) and 6 injectables) are pending approval

Portfolio of R&D products – Filings and Approvals

Dosage (Orals)

- **Filed 86 ANDAs in the US**
 - 56 ANDAs have been approved and 30 ANDAs are pending approval
 - Filed 3 ANDAs in 9M'FY 18

- **Made 809 filings in ROW markets including Canada, Europe and Japan**
 - 607 filings have been approved and 202 filings are pending approval
- **In-licensing of two products in the US market**

Injectable and Others

- Total 4 ANDAs filed and approvals for 2 have been received


Radiopharmaceuticals

- **Filing status as on Dec 31, 2017:**
 - 8 approved registrations in the US
 - 13 registrations in Canada which are all approved
 - 10 registrations in Europe which are all approved
 - In ROW, we have a total of 44 registrations/licenses, of which 4 are pending for approval


- Plan to launch 5 products in next three to four years' time

LSI Segment Highlights

Region-wise Revenue (Rs crs)	Q3'FY17	Q2'FY18	Q3'FY18	Mix %	YoY %	QoQ %
International	273	308	371	40%	36%	21%
Europe, North America and Japan	192	187	242	26%	27%	30%
ROW	81	121	129	14%	58%	7%
India	360	430	551	60%	53%	28%
Income from Operations	633	738	922	100%	46%	25%




Region-wise Revenue (Rs crs)	9M'FY17	9M'FY18	Mix %	YoY %
International	810	992	42%	22%
Europe, North America and Japan	575	633	27%	10%
ROW	235	358	15%	52%
India	1,022	1,369	58%	34%
Income from Operations	1,832	2,361	100%	29%




- Nutritional Products:
 - Received WHO GMP compliance certification for Vitamins which will help us increase our footprint in the premium food and multi-vitamin business, with better realizations
 - Prices maintained at healthy levels for the quarter
- Life Science Chemicals:
 - Better demand for acetyl products with favorable price environment during the quarter.
 - At SEZ Bharuch, capacity enhancement underway for acetic anhydride, with target completion in FY19. Expected revenue at full capacity utilization about Rs. 300 crores
- Ethanol:
 - 4th largest ethanol supplier in the government blending program. Won a new contract to generate revenues of Rs. 300 Crore from Dec'17 to Nov'18
 - Greater availability of molasses with better pricing
- Fine Ingredients:
 - Launch 6 new products during the year and 4 more to be launched in next one year
 - Some De-bottlenecking initiatives completed and underway to meet additional demand
 - Commissioned an Agrochemical intermediate facility which has a total annual revenue potential of around Rs. 50 Crore

Drug Discovery Solutions Segment Highlights

Region-wise Revenue (Rs crs)	Q3'FY17	Q2'FY18	Q3'FY18	Mix %	YoY %	QoQ %
International	43	43	43	97%	0%	1%
North America	32	33	27	60%	-17%	-19%
Europe & Japan	10	8	16	35%	56%	91%
ROW	1	1	1	2%	-17%	-39%
India	0	1	1	3%	431%	21%
Income from Operations	44	44	45	100%	2%	2%



Geo-wise Revenue (Rs crs)	9M'FY17	9M'FY18	Mix %	YoY %
International	130	127	98%	-2%
North America	94	90	69%	-4%
Europe and Japan	33	34	26%	4%
ROW	3	3	2%	10%
India	1	3	2%	117%
Income from Operations	131	130	100%	-1%



Expenditure Analysis – Q3'FY18

Expenses (Rs Crs)	Q3'FY17	% of Sales	Q2'FY18	% of Sales	Q3'FY18	% of Sales	YoY Growth %	QoQ Growth %
Material Cost and Change in Inventory	428	29%	556	34%	707	34%	65%	27%
Purchases of stock-in-trade	61	4%	52	3%	79	4%	30%	53%
Employee benefits expense	309	21%	369	22%	423	20%	37%	15%
Power and fuel expense	83	6%	103	6%	120	6%	45%	16%
Others	245	17%	256	16%	322	16%	31%	25%
Total Expenses (Excluding Excise Duty)	1,126	77%	1,336	81%	1,651	80%	47%	24%
Depreciation and Amortization	73	5%	79	5%	82	4%	13%	4%
Total Finance Costs	98	7%	66	4%	77	4%	-22%	17%
Borrowing costs	89	6%	56	3%	57	3%	-36%	1%
Stock Settlement Instrument Charge	10	1%	10	1%	20	1%	111%	104%

- **Material Costs** as percentage of sales increase due to higher growth in LSI business
- **Power & Fuel** as percentage of sales stable
- **Employee benefits expenses** increase due to acquisition of Triad
- **Other Expenses** increase due to increase in freight & forwarding and legal, professional & consultancy charges
- **Total Finance costs** higher QoQ due to increase in charge on stock settlement instrument, a non-cash debit to P&L, on account of convertible instrument issued to IFC of US\$ 58.2 Million as a mandatory conversion option at IPO of JPL

Expenditure Analysis – 9M'FY18

Expenses (Rs Crs)	9M'FY17	% of Sales	9M'FY18	% of Sales	YoY Growth %
Material Cost and Change in Inventory	1,266	30%	1,809	34%	43%
Purchases of stock-in-trade	143	3%	169	3%	18%
Employee benefits expense	906	21%	1,102	21%	22%
Power and fuel expense	241	6%	313	6%	30%
Others	667	16%	812	15%	22%
Total Expenses (Excluding Excise Duty)	3,223	76%	4,205	80%	30%
Depreciation and Amortization	216	5%	233	4%	8%
Total Finance Costs	261	6%	212	4%	-19%
Borrowing costs	233	5%	168	3%	-28%
Stock Settlement Instrument Charge	28	1%	44	1%	55%

- **Material Costs** as percentage of sales increase due to higher growth in LSI business
- **Power & Fuel** as percentage of sales stable
- **Employee benefits expenses** increase due to annual increments and acquisition of Triad
- **Other Expenses** increase due to increase in freight & forwarding and legal, professional & consultancy charges
- **Total Finance costs** lower 19% YoY. This includes charge on stock settlement instrument, a non-cash debit to P&L, on account of convertible instrument issued to IFC of US\$ 58.2 Million as a mandatory conversion option at IPO of JPL

Debt Profile

Particulars	31-Mar-17	30-Sep-17	31-Dec-17
Foreign Currency Loans	(\$ Mn)	(\$ Mn)	(\$ Mn)
Standalone	19	19	0
Subsidiaries	407	392	374
Total	426	411	374
Rupee Loans	(Rs. Crs)	(Rs. Crs)	(Rs. Crs)
Standalone	1,241	1,214	1,227
Subsidiaries	82	96	101
Total	1,323	1,310	1,327
Gross Debt	(Rs. Crs)	(Rs. Crs)	(Rs. Crs)
Standalone	1,361	1,335	1,227
Subsidiaries	2,723	2,655	2,488
Total	4,084	3,990	3,715
Cash & Equivalent	460	332	269
Net Debt	3,625	3,659	3,446
Change in debt on account of exchange rate difference from 31-March, 2017	-	-18	36
Net Debt - Adjusted for foreign exchange difference	3,625	3,641	3,482
Reduction in Net Debt from March,2017 Adjusted for Exchange Diff.		16	-143
Closing Exchange Rate (Rs./USD)	64.85	65.28	63.88

- **Net debt** at Rs. 3,482 Crore compared to Rs. 3,625 Crore on 31-Mar-17 on constant currency basis
 - Debt reduction of Rs. 159 Crore during the quarter and Rs. 143 Crore for 9M'FY18
- **Average blended interest rate** for 9M'FY18 at 5.93% pa – Re loans @ 8.16%, \$ loans @ 4.66%
- Stock Settlement Instrument (IFC) of US\$ 58.2 Million at 10% per annum discount to Jubilant Pharma Limited IPO price

- **Very robust business performance driven by Specialty Pharmaceuticals – Injectables and LSI segment. We are confident of delivering outstanding performance going forward in Q4'FY18 and FY19:**
 - Specialty Pharmaceuticals - Injectables:
 - Continue to deliver exceptional performance in Radiopharmaceuticals and Allergy Therapy Products
 - The strategic acquisition of Triad will help to sustain revenue growth in Specialty Injectables
 - Healthy order book and new customer addition, supported by higher production, will deliver better results in CMO
 - Generics: Muted growth outlook due to sustained pricing pressure in US formulations
 - Life Science Ingredients:
 - Current momentum in revenue growth expected to continue backed by healthy demand and favorable pricing environment
 - Growth in revenues from new product launches, new orders, new capacities coming on stream and debottlenecking of existing plants
 - Drug Discovery Solutions: Focus on integrated programs and in-house proprietary research for out licensing of new molecules

- **We continue our efforts to generate higher operating cash flows and utilize the same for marginal expansion and reduction of debt to further strengthen the balance sheet with improved financial ratios**

For Investors:

Ravi Agrawal

Jubilant Life Sciences Limited
Ph: +91 120 436 1002
E-mail: ravi.agrawal@jubl.com

Siddharth Rangnekar

CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

For Media:

Sudhakar Safaya

Jubilant Life Sciences Limited
Ph: +91 120 436 1034
E-mail: sudhakar.safaya@jubl.com

Sulakshana Mehrotra

Perfect Relations
Ph: +91 9810122728
E-mail: smehrotra@perfectrelations.com